Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Glucagon RTU · 1 trial · 1 indication
Number of subjects with blood glucose \> 70 mg/dL
Frequency of blood glucose \> 70 mg/dL
| Arm | Type | Description |
|---|---|---|
| Glucagon RTU (glucagon injection) | EXPERIMENTAL | Glucagon Ready-to-Use (RTU); 60 μL injection (0.3 mg glucagon) |
| Placebo | PLACEBO_COMPARATOR | Non-active vehicle for Glucagon RTU; 60 μL injection |
| Name | Type | Description |
|---|---|---|
| Glucagon RTU | DRUG | Glucagon RTU is a sterile subcutaneous injectable non-aqueous solution formulation supplied in a vial and administered via syringe. |
| Placebo | OTHER | The placebo is a non-active version of Glucagon RTU formulation, containing the same solvent and excipients (i.e., vehicle). |
Inclusion Criteria: 1. Male or female 2. Aged 18 to 75 years of age, inclusive 3. Symptoms of hypoglycemia that developed after bariatric surgery (Roux-en-Y gastric bypass \[RYGB\] only) in the absence of antidiabetic medications 4. History of bariatric surgery (RYGB only), at least 6 months prior ...
Glucagon RTU is an investigational ready-to-use glucagon formulation being studied for hyperinsulinemic hypoglycemia and hypoglycemia. It is being evaluated for use in patients with hyperinsulinemic hypoglycemia after bariatric surgery and for prevention of exercise-induced hypoglycemia in adults with type 1 diabetes.
Glucagon RTU is being developed by Xeris Biopharma Holdings, Inc., a company traded on the stock exchange under the ticker XERS. The company is conducting clinical trials to evaluate the drug's safety and efficacy in metabolic conditions.
Glucagon RTU is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and effectiveness for treating hypoglycemia-related conditions.
Glucagon RTU has been studied in two completed Phase 2 trials. NCT03770637 evaluated the drug in patients with hyperinsulinemic hypoglycemia after bariatric surgery in the United States. NCT03841526 assessed its use for preventing exercise-induced hypoglycemia in adults with type 1 diabetes in Canada.
Glucagon RTU is a ready-to-use formulation of glucagon, a hormone that raises blood sugar. Unlike traditional glucagon emergency kits that require mixing before injection, this formulation is designed to be used directly without reconstitution, potentially offering greater convenience for managing hypoglycemia.